Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
Become a Member | Sign in
Home>News>This Article

Ezose Sciences Receives Grant from Michael J. Fox Foundation

Published: Thursday, February 20, 2014
Last Updated: Thursday, February 20, 2014
Bookmark and Share
Foundation to apply Ezose’s Glycan Map technology to investigating the role of glycans in Parkinson’s disease.

Ezose’s Glycan Map technology enables automated analysis of glycans, which attach to proteins in the body and affect their biochemical function. The speed, scope, and quantitative power of this technology ho ld the potential for discovering novel glycan changes associated with altered protein function during the onset and progression of wide - ranging diseases, including Parkinson’s disease and other neurological disorders. Glycan s could serve as novel biomarkers for guiding clinical management and drug development and provide insight into disease mechanism and novel drug targets. 

The research funded by the foundation will be performed in Ezose’s laboratories, where the Glycan Map assay will be used to compare glycan profiles in brain - stem tissue from rat models of Parkinson’s disease and control rats over time and with respect to development of symptoms. 

“The Michael J. Fox Foundation has brought a tireless sense of urgency to advancing research in to Parkinson’s disease,” said Ryuichi Kiyama, Ph.D., Chairman and Chief Executive Officer of Ezose. “We look forward to bringing that spirit as well as our technical capabilities to this novel research project.” 

Mark Frasier, Ph.D., Vice President of Research Programs at The Michael J. Fox Foundation, commented: “Two important steps toward the development of a disease - modifying therapy for Parkinson’s are greater understanding of the underlying pathology of the disease and validation of a reliable biomarker. Ezose’s glycan analysis offers a new approach to serve those goals and bring us closer to a Parkinson’s cure.” 

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Ezose Sciences Enters Glycomics Research Agreement with Kyowa Hakko Kirin
Kyowa Hakko Kirin to Fund Projects Exploiting Ezose’s GlycanMap® technology.
Tuesday, January 29, 2013
Ezose Sciences and Hirosaki University to Collaborate in Glycomics Research
International study will focus on urologic cancers through use of Ezose’s GlycanMap® platform.
Wednesday, May 02, 2012
Scientific News
NIH Supports New Studies to Find Alzheimer’s Biomarkers in Down Syndrome
Initiative will track dementia onset, progress in Down syndrome volunteers.
New Gene Map Reveals Cancer’s Achilles’ Heel
Team of researchers switches off almost 18,000 genes
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
New Way to Force Stem Cells to Become Bone Cells
Potential therapies based on this discovery could help people heal bone injuries or set hardware, such as replacement knees and hips.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos